Education
About Us
Working with TipRanks
Follow Us
Arrowhead Pharmaceuticals (ARWR)
NASDAQ:ARWR
ARWR Analyst Ratings
Strong Buy
7 Buy
2 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ARWR Stock 12 Month Forecast
Average Price Target
$67.50
▼(-3.70% Downside)
| Highest Price Target$85.00 | Average Price Target$67.50 | Lowest Price Target$48.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
RBC Capital
$52→$80
Buy
14.14%
Upside
Reiterated
12/11/25
H.C. Wainwright
$85
Buy
21.27%
Upside
Reiterated
12/09/25
Analyst Recommends Buy Rating for Arrowhead Pharmaceuticals Due to Promising Obesity Treatment PotentialValuation and Risks. We assess Arrowhead using a risk-adjusted discounted cash flow (DCF)- and sum-of-the-parts (SOTP)- based methodology based on free cash flow to the firm (FCFF) and net income per asset, respectively. We assign probabilities of success for plozasiran of 100% (vs. 95% prior) in 90% (vs 80% prior) in sHTG; we assign a POS of 70% for zodasiran in HoFH; we assign a POS of 10% for ARO-RAGE; on the partnered programs, 85% for fazirsiran (formerly for olpasiran (formerly in MASH.
Bank of America Securities
$62→$81
Buy
15.57%
Upside
Reiterated
12/08/25
Morgan Stanley
$48
Hold
-31.52%
Downside
Reiterated
12/08/25
Cautious Optimism for Arrowhead Pharmaceuticals Amid Competitor's Positive Obesity Treatment DataWe note the 240mg dose drove a 78% reduction in Activin E while all treatment related adverse events (TRAEs) were mild in doses up to 600mg. We view these data as encouraging, suggesting silencing INHBE has the potential to reduce fat mass while preserving lean mass and greater knockdown could drive greater benefits, without meaningful toxicity. As a reminder (notes here and here), Arrowhead is evaluating ARO-INHBE (INHBE targeting siRNA) and ARO-ALK (adipose tissue target in Activin E pathway) in Ph1/2a trials and initial data are expected during the first week of January followed by a more fulsome update expected later in 2026.
Piper Sandler
$70
Buy
-0.13%
Downside
Reiterated
12/01/25
TD Cowen
―
Buy
―
Reiterated
11/26/25
Leerink Partners
$21→$23
Hold
-67.19%
Downside
Reiterated
09/04/25
Citi
$27.8→$17
Hold
-75.75%
Downside
Reiterated
09/03/25
Bernstein
―
Hold
―
Reiterated
08/22/25
UBS
$63→$12
Hold
-82.88%
Downside
Downgraded
07/21/25
Cantor Fitzgerald
―
Buy
―
Reiterated
05/13/25
Chardan Capital
$60
Buy
-14.40%
Downside
Reiterated
02/11/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
RBC Capital
$52→$80
Buy
14.14%
Upside
Reiterated
12/11/25
H.C. Wainwright
$85
Buy
21.27%
Upside
Reiterated
12/09/25
Analyst Recommends Buy Rating for Arrowhead Pharmaceuticals Due to Promising Obesity Treatment PotentialValuation and Risks. We assess Arrowhead using a risk-adjusted discounted cash flow (DCF)- and sum-of-the-parts (SOTP)- based methodology based on free cash flow to the firm (FCFF) and net income per asset, respectively. We assign probabilities of success for plozasiran of 100% (vs. 95% prior) in 90% (vs 80% prior) in sHTG; we assign a POS of 70% for zodasiran in HoFH; we assign a POS of 10% for ARO-RAGE; on the partnered programs, 85% for fazirsiran (formerly for olpasiran (formerly in MASH.
Bank of America Securities
$62→$81
Buy
15.57%
Upside
Reiterated
12/08/25
Morgan Stanley
$48
Hold
-31.52%
Downside
Reiterated
12/08/25
Cautious Optimism for Arrowhead Pharmaceuticals Amid Competitor's Positive Obesity Treatment DataWe note the 240mg dose drove a 78% reduction in Activin E while all treatment related adverse events (TRAEs) were mild in doses up to 600mg. We view these data as encouraging, suggesting silencing INHBE has the potential to reduce fat mass while preserving lean mass and greater knockdown could drive greater benefits, without meaningful toxicity. As a reminder (notes here and here), Arrowhead is evaluating ARO-INHBE (INHBE targeting siRNA) and ARO-ALK (adipose tissue target in Activin E pathway) in Ph1/2a trials and initial data are expected during the first week of January followed by a more fulsome update expected later in 2026.
Piper Sandler
$70
Buy
-0.13%
Downside
Reiterated
12/01/25
TD Cowen
―
Buy
―
Reiterated
11/26/25
Leerink Partners
$21→$23
Hold
-67.19%
Downside
Reiterated
09/04/25
Citi
$27.8→$17
Hold
-75.75%
Downside
Reiterated
09/03/25
Bernstein
―
Hold
―
Reiterated
08/22/25
UBS
$63→$12
Hold
-82.88%
Downside
Downgraded
07/21/25
Cantor Fitzgerald
―
Buy
―
Reiterated
05/13/25
Chardan Capital
$60
Buy
-14.40%
Downside
Reiterated
02/11/25
Best Analysts Covering Arrowhead Pharmaceuticals
1 Month
xxx
Success Rate
15/25 ratings generated profit
Average Return
+5.66%
reiterated a xxx
rating 13 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 60.00% of your transactions generating a profit, with an average return of +5.66% per trade.
3 Months
xxx
Success Rate
16/26 ratings generated profit
Average Return
+25.54%
reiterated a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 61.54% of your transactions generating a profit, with an average return of +25.54% per trade.
1 Year
Success Rate
15/26 ratings generated profit
Average Return
+97.68%
reiterated a buy rating 5 days ago
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 57.69% of your transactions generating a profit, with an average return of +97.68% per trade.
2 Years
xxx
Success Rate
22/26 ratings generated profit
Average Return
+164.31%
reiterated a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 84.62% of your transactions generating a profit, with an average return of +164.31% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
ARWR Analyst Recommendation Trends
Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
9
9
10
6
4
Buy
2
5
6
10
14
Hold
19
19
16
10
8
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
30
33
32
26
26
Each month's total comprises the sum of three months' worth of ratings.
ARWR Financial Forecast
ARWR Stock Forecast FAQ
What is ARWR’s average 12-month price target, according to analysts?
Based on analyst ratings, Arrowhead Pharmaceuticals’s 12-month average price target is 67.50.
What is ARWR’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for ARWR, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ARWR a Buy, Sell or Hold?
Arrowhead Pharmaceuticals has a consensus rating of Strong Buy which is based on 7 buy ratings, 2 hold ratings and 0 sell ratings.
What is Arrowhead Pharmaceuticals’s price target?
The average price target for Arrowhead Pharmaceuticals is 67.50. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $85.00 ,the lowest forecast is $48.00. The average price target represents -3.70% Decrease from the current price of $70.09.
The highest analyst price target is $85.00 ,the lowest forecast is $48.00. The average price target represents -3.70% Decrease from the current price of $70.09.
What do analysts say about Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
How can I buy shares of ARWR?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.